Trial Profile
A phase 1b/2, open-label, multicenter, randomized clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PEGPH20 in combination with atezolizumab compared with the standard chemotherapy regimens in patients with previously treated, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Oct 2017
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Hyaluronidase (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genentech
- 26 Oct 2017 New trial record
- 24 Oct 2017 According to a Halozyme Therapeutics media release, the study will be conducted in the U.S., as well as countries outside the U.S. The overall analysis plan includes a retrospective analysis of the HA-high population identified using the Ventana HA companion diagnostic assay.
- 24 Oct 2017 According to a Halozyme Therapeutics media release, first gastric cancer patient has been dosed in the trial.